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Objective: Menopause is associated with lower peripheral vascular function however 
cerebrovascular responses to this time-period are unclear. We aimed to describe peripheral 
vascular and cerebrovascular differences between pre- and post-menopausal women. 
Methods: Fifty pre- and post-menopausal women (N=100) underwent assessments of 
cerebral blood flow, cerebrovascular reactivity and autoregulation, carotid artery reactivity, 
brachial and femoral artery flow-mediated dilation and carotid, brachial and femoral artery 
intima-media thickness. Comparisons were made between pre- and post-menopausal women 
followed by a secondary-analysis (N=20) between late-pre-menopausal women and those 
within five years of menopause using a general linear model. 
Results: Cerebral blood flow (-11 [-17, -4 cm/s]; p=0.03) and carotid reactivity (-2.3 [-4.3, -
0.3%] p=0.03) were lower post-menopause compared to pre-menopause while 
cerebrovascular reactivity and autoregulation did not differ (p>0.05). Post-menopausal women 
had a larger carotid (0.16 [0.13, 0.20 mm] p<0.001), brachial (0.07 [0.03, 0.11mm] p=0.004) 
and femoral artery intima-media-thickness (0.09 [0.05, 0.14 mm] p=0.04), alongside lower 
brachial (-2.3 [-3.9, -0.7%] p=0.004) and femoral artery flow-mediated dilation (-3.0 [-4.3, -
1.8 %] p<0.001). In the secondary-analysis, early-post-menopausal women had a lower 
femoral artery flow-mediated dilation (-1.9 [-3.9, -0.0 %] p=0.05) and larger carotid intima-
media-thickness (0.07 [0.00, 0.14 mm] p=0.03) compared to late-pre-menopausal women. 
Conclusions: Cerebral blood flow, carotid artery reactivity, peripheral vascular function and 
structure are negatively affected by age. Preliminary data indicates that femoral artery function 
and carotid artery structure may be potentially impaired in early-post-menopause compared 
with late-pre-menopause. These findings suggest that conduit arteries susceptible to 
atherosclerosis may be important targets for lifestyle intervention in early menopause.  
 










Age is an independent determinant of cardiovascular disease (CVD) 1 and is accompanied by 
increased traditional CVD risk factors, including body mass index (BMI), blood pressure (BP), 
and cholesterol levels 2. For women, increased CVD risk coincides with the onset of 
menopause, characterised by a reduction in the sex hormone oestrogen 3. As a result, the 
menopause is associated with a greater decline in peripheral vascular function compared to 
pre- and peri-menopause via diminished nitric oxide bio-availability at the endothelium 4. 
However, the functional and structural adaptations that arise at various other vascular beds 
during and following the menopause remain unclear. 
Ageing is associated with the incidence of cerebrovascular diseases such as vascular 
dementia 5 with greater prevalence in women compared to men 6. It has been inferred that the 
menopause may contribute to cerebrovascular disease development 7,8 however, limited 
evidence regarding the additive effect of menopause and ageing on female cerebrovascular 
function makes this difficult to determine. Cerebral blood flow, as measured via middle 
cerebral artery velocity (MCAv), declines in ageing men 9 and is associated with CVD and 
neurodegenerative disease 10. This may be different for women given that the cerebral blood 
vessels contain oestrogen receptors that participate in the release of nitric oxide facilitating 
vasodilation 11.  MCAv has shown to be comparable between pre-menopausal (PRE-M) and 
post-menopausal (POST-M) women, although some women included in this dataset were 
taking hormone therapy 12. Furthermore, MCAv is reportedly unchanged in women following 
surgical menopause 13 implying that ageing and not the immediate oestrogen reduction to be 
responsible for reduced MCAv. Elsewhere however, characteristics of MCAv waveforms have 
been shown to differ between pre- and post-menopausal with potential to provide 
pathophysiological insight into cerebrovascular disease that accompanies age 14. The 
evidence regarding cerebrovascular reactivity (CVR); a marker of cerebrovascular function, is 
conflicting having been reported as lower 12,15 and unchanged 16 in POST-M compared to PRE-




PRE-M assessed using the breath hold index 12. Contrastingly, cerebral autoregulation 
appears unaffected by menopause where elderly women have been compared to age 
matched men, implying no implication of oestrogen reduction on cerebral autoregulation 17. 
However, no study has measured various parameters of cerebrovascular function in a large 
cohort of POST-M women to elucidate cerebrovascular health during the early and latter years 
of menopause. Contrasting findings between studies, different measurement techniques 12,16, 
small sample sizes 16 and liberal inclusion criteria such as elderly people with illnesses15  and 
cohorts including women taking hormone therapy 16 prevent any meaningful consensus being 
reached on the effect of menopause on cerebrovascular function and thus, provide rationale 
for the current study. 
Physical activity (PA) and exercise are important modifiable lifestyle factor that improves 
cardiorespiratory fitness, and enhances peripheral vascular function 18,19, MCAv 20 and CVR 
in post-menopausal women 21. PA levels and fitness may therefore be critical confounders in 
any study which aims to assess vascular outcomes in POST-M women. Yet, no study has 
attempted to objectively quantify PA and CRF in conjunction with cerebral and peripheral 
vascular parameters between pre and post-menopausal women. Therefore, the primary aim 
of this study was to describe the peripheral and cerebrovascular changes that arise from pre- 
to post-menopause with simultaneous assessment of PA and CRF. We hypothesise that PRE-
M women will have higher peripheral and cerebrovascular function compared with POST-M 
women. We also hypothesise that fitness and PA levels will be higher in PRE- compared with 
POST-M women. 
Materials and Methods 
Participants 
Females (n=100) aged between 18-70 years were recruited from the local community through 
social media advertisements and word of mouth over an 18-month period between April 2016 




disease (CVD) and were not on any form of medication. PRE-M women were defined as 
eumenorrheic having a consistent menstrual cycle for at least 3-months and were not on any 
form of hormone-based contraception. POST-M women were recruited based on having no 
menstrual cycle for at least 12 consecutive months and were not previously or currently taking 
any form of hormone therapy 4. Each participant provided written informed consent before 
taking part in the experimental procedure. The research study was ethically approved by the 
Liverpool John Moores School of Sport and Exercise Science Research Committee 
(Reference: 16/SPS/022) and adhered to the Declaration of Helsinki. 
Experimental Procedure 
Participants visited the laboratory on two occasions following abstinence from exercise for 24 
hours and alcohol for 12 hours, as well as any food/caffeine/stimulants six hours prior to the 
experiment. Participants completed a battery of CV and cerebrovascular assessments in the 
following sequence: intima-media thickness (IMT), flow-mediated dilation (FMD), pulse-wave 
velocity (PWV), carotid artery reactivity (CAR), CVR, and cerebral autoregulation, followed by 
seven days of PA and sedentary behaviour monitoring. A maximal CRF test on a cycle 
ergometer was scheduled within seven days of the vascular measurements based on 
participant’s preference. All visits were completed at the same time of day (between 8-11am) 
in a temperature-controlled environment (20-22°C). Eumenorrheic women completed the 
laboratory visit within the first seven days of their menstrual cycle 22. 
Anthropometrics, physical activity and sedentary behaviour  
Anthropometry and Body Composition. Stature and weight were recorded to the nearest 
0.1unit using a stadiometer and digital scales respectively. BMI was calculated as weight in 
kilograms divided by stature in metres squared (kg/m2). Body fat percentage was estimated 
using bioelectrical impedance analysis (Tanita BC-420MA, Tanita Corp., Tokyo, Japan).  
Cardiorespiratory Fitness Test. A ramp-based cycling protocol was used to determine 




participants were no longer able to maintain a pedal speed of at least 50 rpm. Breath-by-
breath oxygen uptake (V̇O2) and carbon dioxide (CO2) were measured via an online gas 
analysis system (Jaeger Oxycon Pro, Viasys Health Care, Warwick, UK). Heart rate (HR) was 
monitored continuously using short-range telemetry (Polar, Kempele, Finland). Participants 
completed a 5-minute warm up at a self-selected resistance. The test began with 50 W of 
resistance and increased by 30 W every two minutes. During the final 20 seconds of each 
stage, participants were asked to rate their exertion, using the Borg rating of perceived 
exertion (RPE) scale 23, and HR was recorded. Criteria for participants reaching their maximal 
capacity was achieving a respiratory exchange ratio of >1.15, a HR >199 bpm and/or an RPE 
of 20 on the Borg RPE Scale 24. The V̇O2 data was exported in 10 second averages for the 
duration of the test to an Excel file and plotted on a graph with time on the x-axis and 
V̇O2·ml·kg·min on the y-axis. The highest value over 30 seconds was extracted as the V̇O2max 
value. 
Physical Activity (PA). PA was monitored using a tri-axial accelerometer (Actigraph wGT3x-
BT, Pensacola, Florida) worn on the right hip for consecutive days. Participants removed the 
device for sleeping, contact sports and water-based activities and recorded the times the 
device was worn on a diary sheet provided. Non-wear time was defined as 90 consecutive 
minutes of zero counts·min-1 25. Inclusion criteria for analysis were ≥10 hours of wear time per 
day, for a minimum of four days, including one weekend day 26. Actilife software, version 6.2 
(ActiGraph, Pensacola, Florida) was used to download the data from the accelerometer to a 
computer. Raw acceleration data was converted to 60s-epoch activity count data (counts∙min-
1). PA intensity was determined using the following cut points 27: light (≤2689 counts·min-1), 
moderate (≤6166 counts·min-1), and vigorous (>6167 counts·min-1). Activity data were 
exported and handled in Excel (Microsoft) and total time (minutes) spent in light, moderate 
and vigorous intensity PA was calculated. To account for any differences in accelerometer 




Sedentary Behaviour. Sedentary time was objectively measured using an activPAL activity 
monitor (activPAL micro, PAL Technologies Ltd., Glasgow, UK) worn continuously for seven 
days on the middle anterior of the right thigh. Monitors were enclosed in a rubber sleeve and 
attached by the researcher to the skin using a waterproof transparent seal (Tegaderm Roll, 
3M). The monitor quantified the time spent sitting/lying per day. A sedentary bout was defined 
as no activity registered for at least 60 seconds 28. The raw data was downloaded from the 
monitor using the activPAL proprietary software (version 7.2.32) from which data were 
exported to Excel. Average daily sedentary behaviour was calculated in seconds during self-
reported waking hours and converted to minutes.  
Cerebrovascular Measurements 
Middle Cerebral Artery Blood Flow Velocity (MCAv). MCAv was measured at rest using a 2 
MHz pulsed transcranial Doppler (TCD) ultrasound system (DWL, Compumedics, Dresden 
Germany). The participant was fitted with a headband which supported an ultrasound probe 
on each side of their head. Ultrasound gel was applied to the temporal window (just above the 
zygomatic arch) and to the probes allowing an optimal signal to be obtained. To insonate the 
correct vessel, specific criteria were followed with the mean and peak MCAv values above 50 
cm·sec-1 and 80 cm·sec-1 respectively and depth set between 40-60 mm 29. Care was taken 
to stabilise the probes ensuring a consistent angle of insonation, in line with best practice 
guidelines 30,31. Simultaneously, arterial BP was monitored non-invasively using a 
photoplethysmographic cuff (Finapres Medical Systems, Enschede, Netherlands) which was 
carefully fitted on the middle or index finger of the participant’s right hand as per 
manufacturer’s recommendations. Real time MCAv and BP were recorded online and 
displayed in LabChart Pro version 7 (ADInstruments, Colorado Springs, CO). The weighted 
mean MCAv was calculated from the peak envelope of the velocity trace (1/3 systolic + 2/3 
diastolic), which accounts for the relative time spent in each phase of the cardiac cycle 32. 
Data were expressed as cerebrovascular conductance (CVC), which was calculated as MCAv 




obtainable, bilateral MCAv was recorded during all cerebral tests. Mean MCAv was calculated 
when bilateral MCAv was recorded. 
Cerebrovascular Reactivity (CVR). Cerebrovascular reactivity to perturbations in partial 
pressure of oxygen (PaCO2) was measured using a hypercapnic rebreathing protocol 32. 
Participants were instrumented as above with the addition of a rebreathing apparatus 
consisting of a mouthpiece, nose clip, a bacteriological filter and a three-way valve to allow 
switching of airflow between room air and a pre-filled Douglas bag containing a hypercapnic 
gas mixture of 5% CO2 and 21% O2, balanced with nitrogen. Breath-by-breath CO2 was 
sampled using a calibrated gas analyzer (Ml206, ADInstruments, Oxford, UK) and the 
pressure of end-tidal carbon dioxide (PETCO2) was recorded online (LabChart) and corrected 
for the daily barometric pressure. A one-minute baseline recording was followed by a period 
of voluntary hyperventilation (1 breath per second) coached by the researcher until a reduction 
in PETCO2 to <20 mmHg. Once achieved, the valve on the Douglas bag was switched so 
participants inhaled the 5% CO2 mixture. Simultaneously, participants were instructed to return 
their respiratory rate to normal whilst breathing the 5% CO2 mixture for 3-minutes. Data was 
exported from LabChart.  
Baseline PETCO2 and MCAv were calculated as the mean of the 1-min prior to 
hyperventilation, while MCAv and PETCO2 data during 5% CO2 breathing was collected as 
10-second averages for the entire 3-minute period. Absolute MCAv and relative changes were 
plotted against PETCO2 for each 10-sec of 5% CO2 of breathing and reported as absolute and 
relative CVR sensitivity (cm/s per mmHg). CVR was subsequently quantified by linear 
regression (R2 value). Relative MCAv was calculated as the difference between baseline and 
5% CO2 MCAv divided by baseline MCAv (([5% CO2 MCAv-baseline MCAv]/ baseline MCAv) 
x 100%) 32,33. Simultaneously, during the baseline and CO2 breathing measurements, arterial 
diameter and blood velocity of the left common carotid artery (CCA) were acquired at least 
two centimeters below the point of bifurcation using high resolution ultrasound. Images were 




response of the CCA to elevations in PETCO2 by averaging 30-sec of baseline diameter and 
comparing that to the diameter during the last 30-sec of 5% CO2 breathing.  
Cerebrovascular Autoregulation. Changes in BP and MCAv were assessed using a squat to 
stand procedure in order to induce transient changes in BP. Participants performed squat-
stand maneuvers at 0.10 Hz (5 second squat - 5 second stand) whilst breathing normal 
atmospheric air for a duration of 6 minutes with PETCO2 monitored throughout. MCAv, 
PETCO2, and beat-to-beat MAP were extracted from LabChart across the 6-minute period. 
The relationship between changes in MCAv and arterial BP was assessed via transfer function 
analysis (TFA) in accordance with standardized guidelines 35. TFA was performed using 
MATLAB (MathWorks-Inc., Natick, MA) in order to calculate associated power (gain) timing 
(phase) and timing normalized to blood pressure (normalized gain) over three different 
frequencies; very low (0.02 – 0.07 Hz), low (0.07 – 0.20 Hz) and high (0.20 – 0.50 Hz) 35. Gain 
rises with increasing BP frequencies and when increased, is indicative of diminished dynamic 
cerebral autoregulation efficiency 36. The second cerebral autoregulation parameter, phase, 
describes the synchronicity of oscillations of BP and MCAv, and a greater phase indicates 
more efficient cerebral autoregulation whereby MCAv and BP waveforms are in sync with one 
another 36. TFA also produces an estimated reliability of the relationship between the two 
signals (coherence) 37. Data sets with a coherence value of <0.4 were excluded from data 
analysis. High frequency and very low frequency range data were excluded from analysis 
based on the frequency of the squat-stands used.  
 
Carotid Artery Reactivity 
In a supine position, left CCA diameter response was measured via ultrasound with 
participant’s neck slightly extended to facilitate adequate imaging. A one-minute baseline 
measurement was recorded, then participants were instructed to immerse their left hand up 
to the wrist into a bucket of icy water (1-5ºC) for three minutes. For the duration of this test, 




to keep as still as possible, without speaking 38. Post immersion CCA data was assessed at 
10-second intervals using the custom designed edge-detection and wall tracking software 
(Dicom Encoder) from which peak diameter change and area under the curve for the diameter 
change during cold pressor test (CARAUC) was calculated. The peak diameter change refers 
to dilation or constriction, and the direction of this change was determined by a positive or 
negative CARAUC (i.e. dilation or constriction respectively). The technique shows a good 
correlation between the CCA diameter response (an extracranial blood vessel) and coronary 
artery flow response in asymptomatic healthy adults, indicating the carotid artery is a valuable 
site in assessing vascular health 38. Taken together, this test can provide information on 
coronary artery vasodilator function and could be a valuable link to evaluating systemic 
vascular health with the menopause and aging in women. 
Cardiovascular measurements 
Carotid, Femoral and Brachial Intima-Media Thickness. Following 20 minutes of rest in a 
supine position, the left CCA was imaged using high-resolution B-mode ultrasound (Terason 
u-smart 3300, Teratech, Burlington, MA) with a 10-12 MHz linear array probe 5 mm proximal 
to the artery bulb 39. Participants lay with neck slightly extended facing the contralateral side 
to allow for optimal longitudinal imaging of the far-wall intima media interface from three angles 
(approximately 45°, 90° and 135°). Images were optimised to ensure clear contrast between 
the artery walls and lumen with a distinct IMT visualised on the far wall defined as the distance 
between two echogenic lines represented by the lumen-intima interface and media adventitia 
interface of the artery wall. The IMT was also acquired at the left femoral artery 3 to 5 cm distal 
to the bifurcation of the femoral artery and left brachial artery 5 to 10 cm above the elbow and 
using the same criteria as for CCA. Each image was recorded by the same sonographer for 
30-40 seconds.  Due to data quality issues, brachial IMT was only obtainable for N=64 women. 
Recordings were analysed offline using the edge detection software Carotid Studio v4.3.1 
(Cardiovascular Suite, Quipu srl, Pisa, Italy) with a frame rate of 25 frames per second. 




minimum length of 1 cm was selected by the researcher. Based on the quality of the scan, a 
5-15 second time frame was chosen for analysis. The automated software produced an edge 
detection output of the near and far-wall media-adventitia interface during each cardiac cycle 
using a pixel-density algorithm. Continuous calculations by the software produced an average 
IMT and artery diameter recorded within the operator selected time duration. This was 
repeated for all three angles and an average of the three angles was calculated. This method 
has been shown to be valid and reproducible 40,41. The extracted data were also used to 
calculate wall-to-lumen ratio (IMT/Lumen) at each arterial site which corrects for differences 
in baseline diameter.  
Arterial Stiffness. Carotid-femoral PWV was assessed using a semi-automated device and 
software (SphygmoCor, AtCor Medical, Sydney, Australia) in the supine position. Firstly, three 
brachial BP measurements were taken in succession (Dinamap V100, GE Medical Systems, 
Germany), with an average systolic (SBP) and diastolic (DBP) calculated and entered into the 
software. A single applanation tonometer probe was used to capture a proximal (carotid artery) 
and distal (femoral artery) pulse, recorded over 10 cardiac cycles. The QRS complex was 
measured simultaneously using electrocardiography (ECG). The time between the R wave of 
the ECG trace and the foot of the proximal waveform is subtracted from the time between the 
R wave and the foot of the distal waveform to obtain the pulse transit time. To determine the 
distance used for PWV, the distance from the proximal measurement site to the suprasternal 
notch was subtracted from the distance between the distal measurement site and the 
suprasternal notch using an anthropometric measuring tape. PWV was automatically 
calculated by dividing the distance between the two arterial recording sites by transit time to 
provide an index of arterial stiffness. PWV measurements were made in triplicate and an 
average was calculated and used in data analysis.  
Brachial and Femoral Flow Mediated Dilation. Left brachial and left femoral artery diameters 
were assessed simultaneously via high resolution 2D duplex ultrasound as per the IMT 




same position for the duration of the test. After 1-minute of baseline measurement, occlusion 
cuffs, connected to a rapid inflator (Hokanson, Bellevue, WA), placed around the left thigh, 
proximal to the patella, and the left forearm, distal to the humeral epicondyle, were inflated to 
a supra-systolic pressure of 220 mmHg for 5-minutes. Arterial images were recorded for a 
further 3-minutes post cuff deflation in accordance with best practice guidelines 42,43. Brachial 
FMD (bFMD) and femoral FMD (fFMD) data were analysed by custom designed edge-
detection and wall tracking software (Dicom Encoder), of which the reproducibility and validity 
have been demonstrated elsewhere 44. An optimal region of interest was selected by the 
sonographer, on the basis of the quality of the distinction between the artery walls and lumen. 
The vessel walls and blood velocity were traced in B-mode frames via pixel density and 
frequency distribution algorithm. The software automatically calculated the relative diameter 
change, time to peak (following cuff release) and shear rate area-under-the-curve (SRAUC). 
The peak artery FMD was defined as the peak percentage change in artery diameter from 
baseline to during 3-minutes post cuff release. Although the initial region of interest selection 
was operator-determined, the remaining analysis was independent of operator bias. FMD data 
was analysed with covariate control for baseline artery diameter (adjusted FMD) allowing FMD 
to be scaled for changes in artery diameter 45.  
Statistical analysis 
All data were analyzed using SPSS (Version 25.0, SPSS, Chicago, IL) and G-Power (version 
3.1). A univariate general linear model was used to analyze the differences between i.) PRE-
M and POST-M women; ii.) a sub-group of 20 pre- (N=10) and post-menopausal women 
(N=10) that were menopausal for <5 years in line with previous work 4. A Pearson correlation 
was performed to statistically examine relations between vascular parameters and potential 
confounders (body fat, V̇O2max, PA and sedentary behaviour). Accordingly, V̇O2max was the only 
confounder significantly related to vascular parameters and was subsequently entered as a 
co-variate into the general linear model. There were no statistically significant correlations 




10 oldest pre-menopausal women (Late-PRE-M), and women who were menopausal for <5 
years (Early-POST-M). This analysis acknowledges the challenge of differentiating between 
the relative contributions from two parallel and intimately linked processes i.e. age and 
menopause and attempts to eliminate the role of age on the vascular measures as significant 
age-related vascular changes are likely to be limited within this short time frame. This study 
achieved >80% power at an α of 0.05 to find between-group differences in our main outcome 
of FMD with an effect size of 0.62 when comparing PRE- and POST-M women. Post-hoc 
power analysis also indicates that in our sub-group, sixteen women are required in each group 
in order to detect a difference of 2.5% in FMD. As such, the data generated from the secondary 
analysis is preliminary and will inform future studies measuring systemic vascular parameters 
around the time of menopause. Data are presented as mean [95% confidence intervals]. Data 




Women were POST-M for 6.5±4.3 years based on the time from their last menstrual period. 
POST-M women had a higher SBP (126 [123, 130 mmHg] p<0.001) and DBP (72 [70, 74 
mmHg] p=0.002) compared to PRE-M women (Table 1). POST-M women had a higher body 
fat (34 [31, 36 %] p=0.09) compared to PRE-M (31 [28, 34%] p=0.09) however this did not 
reach statistical significance. Body mass and BMI were similar between PRE-M and POST-M 
women (p=0.26 and 0.87 respectively). 
In the secondary analysis, the time since the last menstrual cycle for Early-POST-M women 
was 2.6±1.3 years (Table 1). The Late-PRE-M were significantly younger (45.9 [44, 48 years]) 
than the Early-POST-M group (50.4 [48, 52 years] p=0.003) but there were no differences in 
body mass (p=0.48), BMI (p=0.63), body fat (p=0.49), SBP (p=0.85) or DBP (p=0.75) between 





Physical activity, sedentary behaviour and cardiorespiratory fitness 
POST-M women had a significantly lower V̇O2max (24.8 [22.6, 26.9 ml·kg·min]) compared to 
PRE-M (34.7 [32.6, 36.9 ml·kg·min] p<0.001). Daily vigorous PA was significantly lower for 
POST-M women (5 [3, 7 min/d]) compared to PRE-M women (9 [7, 11 min/d] p=0.01). POST-
M women had a lower amount of sedentary time (490 [461, 520 min/d] p=0.09) compared to 
PRE-M women (525 [497, 553 min/d] p=0.09) however this did not reach statistical 
significance. There were no differences between groups for light (p=0.40), moderate PA 
(p=0.24), average daily PA (p=0.81) or accelerometer wear time (p=0.64, Table 1).  Women 
in the Late-PRE-M group performed a greater amount of light PA (354 [292, 415 min/d]) than 
the Early-POST-M group (264 [199, 329 min/d] p=0.05). There were no differences between 
groups for V̇O2max, moderate PA (p=0.25), vigorous PA (p=0.92), average daily PA (p=0.12) or 
sedentary behaviour (p=0.11). Late-PRE-M women had significantly greater accelerometer 




POST-M women had a significantly lower baseline MCAv (61.3 [57, 66 cm/s] p=0.03) and 
CVC (0.53 [0.45, 0.66 cm·s-1·mmHg-1] p=0.02) compared to PRE-M women (Table 2). There 
were no differences between PRE-M and POST-M for PETCO2 (p=0.99), absolute (p=0.52) 
and relative MCA CVR (p=0.18), r2 value (p=0.55), or CCA diameter response to the CVR test 
(p=0.64). In the secondary analysis comparing Late-PRE-M and Early-POST-M, there were 
no differences in baseline MCAv (p=0.91), CVC (p=0.07), PETCO2 (p=0.23) absolute (p=0.79) 
and relative CVR (p=0.99), r2 value (p=0.53), or carotid artery diameter response to the CVR 
test (p=0.25). There were no differences between PRE-M and POST-M women for the 
cerebral autoregulation parameters of normalised gain (p=0.56) and phase (p=0.73) 
measured in the low frequency (Table 2). Similarly, there were no differences between Late-
PRE-M and Early-POST-M women for normalised gain (p=0.77) and phase (p=0.18) 




Carotid artery reactivity 
CAR was significantly lower in the POST-M women (0.7 [-0.7, 2.1%)] compared to PRE-M 
women (3.0 [1.5, 4.4 %] p=0.03) (Table 3). In the secondary analysis, CAR was similar 
between Early-POST-M (0.81 [-2.94, 4.56 %]) and Late-PRE-M (0.77 [-2.98, 4.51 %] p=0.99) 
(Table 3, Figure 1).   
Peripheral Vascular Function  
Brachial Femoral FMD and PWV 
The POST-M women had a significantly lower brachial FMD (4.1 [2.9, 5.2 %]) compared to 
PRE-M women (6.4 [5.4, 7.5%] p=0.004) (Figure 2). The time to peak (TTP) was significantly 
higher in POST-M women (65 [57, 74 seconds]) compared to PRE-M women (46 [39, 54 
seconds] p=0.002). There were no differences between groups for baseline diameter (Dbase) 
(p=0.62), peak diameter (Dpeak) (p=0.75), or shear rate area under the curve (SRAUC) (p=0.10, 
Table 3). POST-M women had a significantly lower femoral FMD (2.8% [1.9, 3.6 %]) compared 
to PRE-M women (5.8 [4.9, 6.7 %] p<0.001) (Figure 2). There were no differences between 
PRE- and POST-M groups for femoral TTP (p=0.15), Dbase (p=0.19), Dpeak (p=0.72), or 
SRAUC (p=0.76) (Table 3). PWV was significantly higher for POST-M women (6.87 [6.5, 7.3 
m/s]) compare to PRE-M women (5.45 [5.1, 5.8 m/s] p<0.001). However, when V̇O2max was 
controlled for, this was not statistically significant (p=0.49). 
 
In the secondary analysis, brachial TTP was higher for Late-PRE-M women (66 [50, 82 
seconds]) compared to the Early-POST-M group (37 [30, 49 seconds] p=0.01). There were 
no significant differences between Late-PRE-M and Early-POST-M women for bFMD 
(p=0.58), SRAUC (p=0.09), Dbase (p=0.73), or Dpeak (p=0.53). Early-POST-M women had a 
significantly lower fFMD (2.1% [0.8, 3.5 %]) compared to Late-PRE-M women (4.1 [2.7, 5.5 %] 
p=0.049) (Figure 3). There were no differences between groups for TTP (p=0.69), Dbase 




responses reported for brachial or femoral arteries (Table 3). PWV was not different between 
Early-POST-M and Late-PRE-M (p=0.84, Table 3). 
 
Carotid and Peripheral Vascular Structure 
Intima Media Thickness 
POST-M had a greater IMT at the carotid (0.70 [0.68, 0.73 mm] p<0.001), brachial (0.38 [0.36, 
0.41mm] p=0.004) and femoral arteries (0.49 [0.46, 0.53 mm] p=0.04) compared to PRE-M 
women (Figure 3, Table 3). POST-M women also had a higher IMT-to-lumen ratio at the 
carotid (0.10 [0.10, 0.11] p<0.001), brachial (0.10 [0.09, 0.11] p=0.001) and femoral arteries 
(0.06 [0.07, 0.08] p<0.001) compared to PRE-M women. Carotid artery diameter was greater 
in POST-M women (6.85 [6.7, 6.9 mm]) compared to PRE-M women (6.6 [6.5, 7.7 mm] 
p=0.014). However, when V̇O2max was controlled for, this was no longer statistically significant 
(p=0.46). 
Early-POST-M women had a significantly larger cIMT (0.67 [0.63, 0.63 mm]) compared to 
Late-PRE-M women (0.59 [0.54, 0.65 mm] p=0.03). There was a trend for a larger brachial 
IMT in the Early-POST-M group (0.34 mm [0.30, 0.37 mm]) compared to the Late-PRE-M 
group (0.30 [0.27, 0.33 mm] p=0.09). There were no differences between groups for femoral 
IMT (p=0.43) (Table 3). Early-POST-M women had a significantly greater carotid IMT/lumen 
(0.10 [0.09, 0.11]) compared to Late-PRE-M women (0.89 [0.09, 0.10] p<0.001). A trend was 
observed towards a larger brachial IMT/lumen artery in the Early-POST-M group (0.09 [0.08, 
0.10]) compared to the Late-PRE-M group (0.08 [0.06, 0.09] p=0.05). There were no 
differences between groups for femoral IMT/lumen (p=0.62). There were no differences 
between groups for carotid artery diameter (p=0.71). Brachial and femoral artery diameters 
are referred to in the FMD section. 
Discussion 
This study aimed to describe the peripheral and cerebrovascular structural and function 




CRF. The findings of this study demonstrate that cerebral blood flow, central and peripheral 
vascular function are lower and artery wall thickness is greater in menopausal women. These 
changes occur with simultaneous reductions in vigorous PA and CRF. The secondary analysis 
performed to generate preliminary data around the time of menopause suggests that only 
femoral FMD and carotid IMT are impaired in early menopausal (<5 years). This proposes 
potential direct effects of oestrogen reduction and not age on large artery structure and 
function however, this warrants further investigation for improved clarification.  Taken together, 
our data illustrates that menopause is accompanied by impaired MCAv, peripheral vascular 
function and structure with some site-specific decrements potentially evident early in the 
menopausal transition.  
Cerebral blood flow, measured via MCAv, was lower in PRE-M compared to POST-M 
however, this was not apparent in the early years of menopause suggesting that this lower 
MCAv is likely age-related 9.  Nevertheless, CVR did not differ between PRE-M to POST-M, 
or in the secondary group analysis; in line with previous findings 16. Reduced CVR is more 
commonly associated with populations with overt disease 46,47 and is usually maintained in 
healthy individuals 48 however, the immediate and long term effect of menopause on CVR 
without the inclusion of hormone therapy 13 has been largely unreported. Given the exclusion 
criteria of the current study (i.e. women on medication or with a history of disease) our findings 
suggest that cerebrovascular function is maintained during and following the menopause in 
healthy women with no CVD risk factors or overt CVD.  In contrast to a previous study, cerebral 
autoregulation did not differ between PRE-M to POST-M, or in the secondary group analysis 
in contrast to a previous study 9. This may be explained by differential methods used to assess 
cerebral autoregulation with ours adhering to recommended guidelines for assessing cerebral 
autoregulation 35. In summary, cerebrovascular function appears unaltered with menopause 
despite reductions in MCAv. 
A novel aspect of the current study relates to the assessment of CAR via the cold pressor test. 




blood flow to the brain 49. In addition, the CAR test reflects coronary artery dilatory responses 
38 which may be indicative of coronary artery disease and CV events 50. Thus, taken together 
CAR may provide insight into the interaction between central and cerebral vessels as well as 
central and peripheral vessels. Our data illustrates CAR to be lower in POST-M compared to 
PRE-M however, could potentially be age related since the CAR response was similar 
between Late-PRE-M and Early-POST-M women. Further clarification is required with a larger 
sample around the time of menopause to confirm this. Interestingly, given the extracranial role 
of the carotid artery, the CAR data does not reflect the intact in-tact CVR and autoregulatory 
responses between PRE-M and POST-M women. It does however support the age-related 
reductions in MCAv as well as peripheral artery vascular function (brachial and femoral 
arteries) observed in the current study.  The dilation (or constriction) during the CAR test is 
influenced by sympathetic nerve activity 51, which also increases with age 52. This age-
associated increase in sympathetic nerve activity may explain the lower CAR in POST-M 
women. Alternatively, the diminished response at the carotid artery may also reflect 
endothelial dysfunction in line with that observed at the brachial artery as a consequence of 
age. We also included an assessment of femoral artery endothelial function in the current 
study to obtain a systemic view of the vascular system with age and menopause in females 
but also because, like the carotid artery, the femoral artery is susceptible to atherosclerosis 
53. Importantly, we show femoral artery endothelial dysfunction to be evident early in the 
menopausal transition according to our secondary analysis. While this may imply that femoral 
artery dysfunction may be due to menopause transition rather than age, caution is advised 
when interpreting these results given the small sample size involved. Nonetheless, we can 
speculate on the potential mechanisms regarding this. Firstly, this could be explained by 
differences in the contribution of oestrogen to vasodilation in the femoral artery via nitric oxide 
or oestrogen receptors located in the endothelial and smooth muscle cells 54. Alternatively, the 
impairment could be explained by the reduction in PA observed in the current study. It is known 
that artery size influences the shear stimuli and functional responses of an artery 55. An acute 




brachial FMD 56. It is plausible that chronic reductions in PA could exacerbate this response 
further resulting in longer-term femoral artery dysfunction, however this requires further 
clarification. Taken together, the CAR test reflects lower systemic endothelial function in 
POST-M women that is potentially age related. In contrast, lower femoral artery endothelial 
function in POST-M women may be driven by reduced oestrogen and/or physical inactivity, 
however this requires further investigation. Our data supports the concept of site-specific 
arterial adaptation highlighting the need to assess multiple vascular sites in order to gain a 
comprehensive understanding of systemic haemodynamics. 
Artery wall thickening at the carotid, femoral and brachial arteries were evident in POST-M 
compared with PRE-M women. Previous research has shown that significant carotid artery 
remodelling occurs post-menopause independent of atherosclerotic risk factors and metabolic 
variables 57. Our preliminary data generated by the secondary analysis supports this, 
suggesting that remodelling may occur early in menopause and is potentially more 
pronounced at the carotid compared with brachial and femoral arteries. Increased BP, which 
exerts a greater distending force on the artery wall is considered an important contributor to 
carotid thickening 58 but elevated BP was not apparent in the early-menopausal period in this 
study. The carotid artery is susceptible to atherosclerosis due to its large artery diameter and 
the greatest shear rate in comparison to the brachial and femoral arteries 59. Although 
speculative, the higher susceptibility of carotid artery wall thickening in early menopause may 
therefore be related to the elastic nature of the artery wall 60. Oestrogen has the ability to 
increase elastin/collagen ratio and attenuate collagen deposition in aortic smooth muscle cells 
in vitro 61,62. Oestrogen reduction may therefore have an opposing effect on the connective 
tissue component of the carotid artery wall leading to increased stiffness and altered structure 
63. In contrast, brachial and femoral arteries are muscular in nature with thicker medial layers 
and more smooth muscle cells compared with elastic arteries 64. Increases in IMT in healthy 
adults are thought to be due to smooth muscle cell hypertrophy within the medial layer, and 




carotid artery wall thickening compared to the periphery however this requires further 
investigation within a larger cohort around the time of menopause. According to previous 
research, maintaining moderate-vigorous PA in early menopause may influence several 
putative factors known to modulate smooth muscle cells in the arterial wall including 
sympathetic-adrenergic activity, circulating ANG II and endothelin-1, and locally released 
vasoactive factors such as nitric oxide 66-68. It would therefore be reasonable to suggest that a 
reduction in this moderate-vigorous PA could compound these vasoactive factors. 
Interestingly, POST-M had a lower level of vigorous PA and simultaneously, a higher brachial 
and femoral IMT in comparison to PRE-M women. Previous findings have shown exercise to 
protect against IMT development in ageing men and women 69. It is understood that exercise 
protects against IMT development by releasing local vasoactive factors at the endothelium to 
counteract vasoconstrictors associated with artery stiffening and wall thickening 66. Acute 
increases in blood flow and a resulting elevation in shear stress 70 is known to increase nitric 
oxide  production 71. The withdrawal of this stimulus may therefore contribute to IMT 
development in the periphery. Taken together, the heterogenous progression of IMT across 
multiple arteries may be explained by differential artery wall properties and the influence of 
PA in attenuating peripheral IMT development. Overall these data imply for the first time, that 
menopausal status may potentially play a role in the regulation of carotid artery structure and 
femoral artery function. Remaining outcomes such as CAR, brachial and femoral structures 
and brachial FMD appear to be more heavily influenced by age. Nonetheless, further 
investigation into the time just before and soon after menopause (<5years) would clarify the 
contribution of age and/or oestrogen reduction on these parameters of central and peripheral 
vascular function and structure. This may influence future study designs protocols where age 
and/or menopause are being investigated. 
 
This study, for the first time, examined important confounders of CVD including body 
composition, aerobic capacity, PA and sedentary behaviour in conjunction with a large battery 




risk in women. Despite 84% of women in this cohort surpassing PA guidelines of 150 min/week 
of moderate to vigorous PA, CRF were lower in PRE-M compared to POST-M women. This 
may be due to the significant reduction in vigorous PA in POST-M women, as vigorous PA 
has been shown to significantly impact CRF. Consequently, in our cohort of healthy women, 
achieving PA guidelines was insufficient to prevent against the presence of  CV risk markers,  
in agreement with existing research 72. Future research should look to identify a dose response 
to vigorous PA and CV risk factors among older women in an attempt to preserve confounders 
of CVD. 
Strengths and Limitations 
 
Firstly, this study is strengthened by a large sample size and the inclusion of a vast range of 
peripheral vascular and cerebrovascular outcomes that are novel risk factors for CVD 
compared to traditional use of fitness and BMI. These techniques have been combined with 
other traditional confounders of CVD risk including body composition, aerobic capacity, 
objectively measured PA and sedentary behaviour that have been typically assessed in 
isolation in this cohort. The wide age range has facilitated two separate analysis to be 
performed providing novel insight between PRE-M and POST-M women and Late-PRE-M and 
Early-POST-M women. For the first time in this cohort, we have applied allometric scaling to 
the brachial and femoral arteries during our FMD analyses to account for changes in baseline 
diameter.  
A key limitation is our cross-sectional study design which limits the ability to monitor changes 
to CV risk parameters over time. As such the interpretation of our findings is limited as we 
cannot definitively determine the CV changes that arise with the ageing process. We 
acknowledge that no metabolic data was collected in this sample including blood glucose and 
lipid profiles which are important contributors to prevalence of CVD. Furthermore, the authors 
did not collect data on the number of women who expressed interest in the study and as such, 
are unable to comment on potential bias of the recruited sample. Additionally, 84% of the 




week which may not be representative of the general female population and may have 
influenced our findings. In the secondary analysis, the authors did not exclude women form 
the late-pre-menopausal group based on vasomotor symptoms and as a result cannot confirm 
if some of these women were peri-menopausal. Importantly, the results of this secondary 
analysis must be interpreted with caution based on the sample size however, we were able to 
show significant statistical differences. Furthermore, we were unable to age match the Early-
Post-M and Late-PRE-M groups, as such we have been unable to wholly remove the influence 
of age in this comparison.  
Conclusion 
 
Female vascular health is multifactorial and cannot be linked solely to oestrogen reduction. 
Our findings demonstrate that cerebral blood flow and peripheral artery function reduce with 
age in healthy women. Furthermore, oestrogen reduction appears to result in an immediate 
lowering of femoral artery function and higher carotid artery wall thickness, which could be 
early targets for intervention during the menopausal period to prevent accelerated vascular 
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Table 1 Participant characteristics, physical activity and sedentary behaviour between PRE-
M and POST-M women and Late-PRE-M and Early-POST-M women.  
Table 2 Cerebral hemodynamic differences between PRE- and POST-M women and Late-
PRE-M and Early-POST-M women. 




Figure 1: Carotid artery reactivity (CAR) for PRE-M and POST-M women (A) and women in 
the secondary analysis (B). CAR is significantly lower in POST-M women compared to PRE-
M women (A). A greater number of POST-M women demonstrate a constriction of the carotid 
artery during the cold pressor test (*p=0.03). Carotid artery reactivity is unchanged in early 
menopause (Early-POST-M) compared to late pre-menopause (Late-PRE-M) (p>0.05) (B). 
Figure 2: Brachial and femoral artery flow-mediated dilation (FMD) for PRE-M and POST-M 
women and Late-PRE-M and Early-POST-M women. Brachial artery FMD is significantly lower 
in POST-M compared to PRE-M women (*p=0.004) although is not different between Late-
PRE-M and Early-POST-M women (p=0.58). Femoral FMD is significantly lower in POST-M 
compared to PRE-M women (†p<0.001) and similarly, is significantly lower in Early-POST-M 
compared to Late-PRE-M women (‡p=0.049). 
Figure 3: Intima-media thickness (IMT) at the carotid, brachial (bIMT) and femoral (fIMT) 









Table 1 Participant characteristics, physical activity and sedentary behaviour between PRE-M and 
POST-M women and Late-PRE-M and Early-POST-M women.  






N 50 50 - 10 10 - 
Time from menopause (y) - 6.5±4.3 - - 2.6 1.3 - 
Age (y) 33.2±9.1 58.5±5.5 <0.001 45.9±3.1 50.4±2.8c 0.003 
Body mass (kg) 68.6±1.9 65.4±1.9 0.25 68.1±6.3 65.8±8.1 0.48 
BMI (kg/m2) 25±6 25±4 0.87 25±3 26±3 0.63 
Body fat (%) 31.2±8.6 34.1±8.0 0.09 33.6±5.9 35.2±5.0 0.49 
V̇O2max (ml·kg·min) 34.8±8.6 24.8±6.2b  <0.001 31.6±6.0 28.2±7.6 0.29 
SBP (mmHg)a 109±8 126±15b <0.001 114±10 115±13 0.85 
DBP (mmHg)a 65±7 72±7c 0.002 69±8 70±8 0.75 
Physical Activity and 
Sedentary Behaviour  
      
Light PA (mins) 285±74 299±88 0.40 354±80 264±104 0.05 
% Wear Time 34±7 35±9 0.88 41±8 35±10 0.41 
Moderate PA (min/d) 55±22 49±24 0.24 43±18 55±23 0.25 
% Wear Time 7±3 6±3 0.94 5±2 8±4 0.38 
Vigorous PA (min/d) 10±9 5±7c 0.01 9±8 9±8 0.92 
% Wear Time 1±1 1±1 0.98 1±1 1±1 0.98 
Average daily PA (min/d) 350±78 353±94 0.81 406±85 328±118 0.12 
Average daily wear time 
(min/d) 
832±140 846±135 0.64 858±101 743±118c 0.04 
Average daily sedentary 
time (min/d) 
524±80 490±100 0.09 519±55 445±108 0.11 
Values are mean ± SD. Abbreviations: PRE-M; pre-menopause, POST-M, post-menopause, Late-
PRE-M; late pre-menopause, Early-POST-M; early post-menopause, BMI; body mass index, 
V̇O2max; maximal oxygen consumption, SBP; systolic blood pressure, DBP; diastolic blood 















Table 2 Cerebral hemodynamic differences between PRE-M and POST-M women and Late-PRE-M 
and Early-POST-M women. 
 PRE-M POST-M p-value Late-PRE-M Early-POST-M p-value 
PETCO2 (mmHg) 36.2±3.2 36.2±3.6 0.99 36.3±3.3 41.9 ± 13.6 0.23 
MCAv (cm/s-1)a 72.0±14.9 61.3±15.4c 0.03 68.9±6.0 68.2±16.3 0.91 
CVC (cm·s-1·mmHg-1)a 0.79±0.33 0.53±0.32c 0.02 0.82±0.12 0.56±0.41 0.07 
MAP (mmHg)a 80±7 90±9b <0.001 83±9 88±8 0.62 
Hypercapnic CVR test     
PETCO2 (mmHg) 44.9±2.1 44.5±3.5 0.97 45.1±2.1 45.0±3.0 0.99 
Carotid Diameter (mm) 6.46±0.01 6.64±0.01 0.18 6.37±0.17 6.28±0.17 0.72 
Carotid Diameter (mm) 
(last 30 seconds) 
6.49±0.06 6.37±0.15 0.64 6.45±0.24 6.86±0.25 0.25 
CVR (r2) 0.82±0.08 0.81±0.09 0.55 0.83±0.07 0.80 ± 0.11 0.53 
Absolute CVR 
(cm·s·mmHg-1) 
3.76±1.48 3.51±1.92 0.52 4.03±1.56 4.31 ±2.58 0.79 
Relative CVR 
(cm·s·mmHg-1) 
4.84±1.99 5.47±2.17 0.18 5.43±2.51 5.45 ± 2.36 0.99 
Autoregulation                                         
PETCO2 (mmHg) 38.2±2.5 38.0±2.1 0.98 37.1 1.1 37.4 2.0 0.97 
MAP (mmHg) 80±9 89±7 0.10 84±3 88±5 0.58 
Normalised gain (%) 1.35±0.37 1.30±0.40 0.56 1.35±0.29 1.31±0.28 0.77 
Gain (cm·s·mmHg)a 0.98±0.22 0.72±0.22b <0.001 0.92±0.17 0.83±0.19 0.35 
Phase (degrees) 22.61±14.77 23.79±13.22 0.73 24.92±12.65 14.74±11.87 0.18 
Coherence 0.62±0.12 0.67±0.12 - 0.67±0.12 0.62±0.08 - 
Values are mean ± SD. Abbreviations: PRE-M; pre-menopause; POST-M; post-menopause; Late-PRE-
M; late pre-menopause, Early-POST-M; early post-menopause,  PETCO2; end tidal carbon dioxide 
MCAv; middle cerebral artery velocity, CVC; cerebrovascular conductance, MAP; mean arterial pressure, 


















 Pulse-Wave Velocity (m/s)a 5.45±0.99 6.87±1.40 0.49 5.87 ± 0.73 5.79 ± 1.05 0.84 
FMD Brachial Artery       
 Baseline artery diameter (cm) 0.34±0.04 0.34±0.04 0.62 0.35±0.04 0.34±0.06 0.73 
 Peak artery diameter (cm) 0.36±0.05 0.35±0.05 0.75 0.37±0.04 0.36±0.07 0.53 
 Time to Peak (secs) 46±23 65±32b 0.002 37±17 66±27b 0.01 
 SRAUC (x103) 16.8±7.7 20.0±10.9 0.10 14.1±6.3 20.9±9.4 0.09 
 FMD (%) 6.4±3.9 4.1±3.4b 0.004 5.3±2.6 4.7±1.2 0.58 
 Adjusted FMD (%) 6.4±0.5 4.2±0.6b 0.007 6.1±1.3 4.0±0.7 0.30 
IMT (N=64) IMT (mm)a  0.31±0.04 0.38±0.08b 0.004 0.30±0.04 0.34±0.30 0.09 
 IMT/Lumen  0.08±0.14 0.10±0.02b 0.001 0.08±0.02 0.09±0.01 0.05 
FMD Femoral Artery          
 Baseline artery diameter (cm) 0.58±0.08 0.60±0.09 0.19 0.60±0.06 0.62±0.05 0.80 
 Peak artery diameter (cm) 0.61±0.08 0.62±0.09 0.72 0.61±0.06 0.63±0.05 0.86 
 Time to Peak (secs) 60±33 71±36 0.15 63±48 71±39 0.69 
 SRAUC (x103) 20.3±16.1 19.3±13.2 0.76 17.3±8.8 17.3±11.2 0.99 
 FMD (%) 5.8±4.1 2.8±2.3c <0.001 4.1±1.9 2.1±1.9 0.05 
 Adjusted FMD (%) 6.0±0.4 2.5±0.4c <0.001 5.3±1.1 2.2±1.0 0.05 
IMT IMT (mm)a 0.39±0.09 0.49±0.11b 0.04 0.46±0.08 0.49±0.10 0.43 
 IMT/Lumen  0.07±0.01 0.06±0.01b 0.01 0.08±0.02 0.08±0.02 0.62 
Carotid Artery Lumen artery diameter (mm)a 6.59±0.40 6.85±0.53  0.46 6.61±0.30 6.72±0.54 0.71 
 IMT (mm)a 0.54±0.07 0.70±0.08c  <0.001 0.59±0.07 0.67±0.09b 0.03 
 IMT/Lumen  0.08±0.01 0.10±0.01c <0.001 0.09±0.01 0.10±0.01b 0.04 
Reactivity CAR (%) 3.0±4.6 0.7±4.9b 0.03 0.8±6.0 0.8±4.5 0.99 
Values are mean ± SD. Abbreviations: PRE-M; pre-menopause, POST-M; post-menopause,  Late-PRE-M; late pre-menopause, Early-POST-M; early post-
menopause, SRAUC; shear rate area under the curve, FMD; flow-mediated dilation, IMT; intima media thickness, IMT/lumen; IMT-to-lumen ratio, CAR; carotid 
artery reactivity.   aV̇O2max treated as covariate, significance is denoted by bp<0.001 and cp<0.05.  
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